As a result, 4 candidates (RPF2, GNL2, NCF4, and NUP133) from these 21 candidates showed positive expression in more than 90% of CDC samples, without high or medium IHC scores in common kidney malignancies, hinting at their potential as diagnostic biomarkers. This evidence concerns the gene GNL2 and urogenital neoplasm.